Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?

Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new “Netflix” style subscription model for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space. 

The Review on Antimicrobial Resistance (AMR) was commissioned in July 2014 by the UK Prime Minister at the time, David Cameron, who asked economist Jim O’Neill to analyze the global problem of rising drug resistance and propose concrete actions to tackle it internationally. (Also see "O'Neill: UK 'Lost Focus' On Antibiotic Crisis And Pharma Must Do More" - Scrip, 23 November, 2017.)

Years later, there is still a bleak picture of the state of AMR globally; the challenges faced by innovative drug...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from C-Suite Speaks

More from Leadership